These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22189487)

  • 21. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
    Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
    Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
    Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
    PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation of Pre-anthracycline Serum Bilirubin Levels to Left Ventricular Ejection Fraction After Chemotherapy.
    Vera T; D'Agostino RB; Jordan JH; Whitlock MC; Meléndez GC; Lamar ZS; Porosnicu M; Bonkovsky HL; Poole LB; Hundley WG
    Am J Cardiol; 2015 Dec; 116(11):1752-5. PubMed ID: 26433273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
    Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
    Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
    Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
    Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.
    Hamirani Y; Fanous I; Kramer CM; Wong A; Salerno M; Dillon P
    Med Oncol; 2016 Jul; 33(7):82. PubMed ID: 27334792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
    Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
    Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
    de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.
    Koelwyn GJ; Lewis NC; Ellard SL; Jones LW; Gelinas JC; Rolf JD; Melzer B; Thomas SM; Douglas PS; Khouri MG; Eves ND
    Oncologist; 2016 Feb; 21(2):141-9. PubMed ID: 26764251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
    Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
    Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
    Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
    Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
    Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
    Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
    J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.